Plasma dynamic monitoring of soluble c-Met level for EGFR-TKI treatment in advanced non-small cell lung cancer

BACKGROUND: The activation of c-Met has been associated with both primary and acquired resistance to EGFR-TKI therapy in NSCLC patients. Thus, c-Met status during EGFR-TKI therapy should receive much attention. RESULTS: Forty-nine patients were selected as training cohort and 52 cases as validation...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Hong-Fei, Yang, Jin-Ji, Chen, Zhi-Hong, Zhang, Xu-Chao, Yan, Hong-Hong, Guo, Wei-Bang, Zhou, Qing, Gou, Lou-Ying, Dong, Zhong-Yi, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129951/
https://www.ncbi.nlm.nih.gov/pubmed/27213587
http://dx.doi.org/10.18632/oncotarget.9425

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5129951/
https://www.ncbi.nlm.nih.gov/pubmed/27213587
http://dx.doi.org/10.18632/oncotarget.9425

Ejemplares similares